Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 11/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4566055 | 0.94 | C3AR1 (0.45) | C3AR1PDPK1 | |
| SCHEMBL4991622 | 0.94 | C3AR1 (0.45) | C3AR1PDPK1 | |
| SCHEMBL4990654 | 0.93 | C3AR1 (0.45) | C3AR1FOLH1PDPK1 | |
| SCHEMBL4990569 | 0.90 | C3AR1 (0.39) | C3AR1BRD4KDM4EALDH1A1HTT | |
| SCHEMBL4425979 | 0.88 | PADI1 (0.40) | C3AR1EPHX2PDPK1 | |
| SCHEMBL4992916 | 0.87 | C3AR1 (0.44) | C3AR1BRD4KDM4EALDH1A1 | |
| SCHEMBL4986529 | 0.87 | C3AR1 (0.43) | C3AR1FOLH1PDPK1 | |
| SCHEMBL4437670 | 0.85 | KMT2A (0.46) | C3AR1KDM4EALDH1A1 | |
| SCHEMBL14090906 | 0.85 | CA1 (0.39) | C3AR1KDM4EALDH1A1PDPK1 | |
| SCHEMBL4989792 | 0.84 | C3AR1 (0.40) | C3AR1KDM4EALDH1A1FOLH1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | C3AR1 1/4885BRD4 2776/4885TPSAB1 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.